Research programme: cell therapy - PanCELLa
Latest Information Update: 28 Nov 2024
At a glance
- Originator panCELLa
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 04 Jan 2023 Pluristyx and panCELLa has patent protection for induced Allogeneic Cell Tolerance (iACT Stealth™) technology in UK
- 12 Oct 2020 Cell therapy - PanCELLa is available for licensing as of 12 Oct 2020. https://pancella.com/ (PanCELLA website, October 2020)